Genfit S.A. (GNFT.PA)
EUR 3.5
(2.04%)
EUR 3.5
(2.04%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -7.61 Million EUR | 87.47% |
| 2022 | -60.72 Million EUR | 67.09% |
| 2021 | -184.52 Million EUR | -1358.5% |
| 2020 | 14.66 Million EUR | 115.74% |
| 2019 | -93.12 Million EUR | -147.32% |
| 2018 | -37.65 Million EUR | 65.79% |
| 2017 | -110.06 Million EUR | 24.62% |
| 2016 | -146.02 Million EUR | -168.4% |
| 2015 | -54.4 Million EUR | 21.61% |
| 2014 | -69.4 Million EUR | -411.37% |
| 2013 | -13.57 Million EUR | -408.58% |
| 2012 | 4.39 Million EUR | 240.69% |
| 2011 | 1.29 Million EUR | 109.26% |
| 2010 | -13.94 Million EUR | -81.89% |
| 2009 | -7.66 Million EUR | -14.06% |
| 2008 | -6.72 Million EUR | 44.6% |
| 2007 | -12.12 Million EUR | 32.45% |
| 2006 | -17.95 Million EUR | -161.61% |
| 2005 | -6.86 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 536 Thousand EUR | 0.0% |
| 2023 FY | -7.61 Million EUR | 87.47% |
| 2023 Q2 | -36.4 Million EUR | 0.0% |
| 2023 Q4 | -7.61 Million EUR | 0.0% |
| 2022 Q2 | -134.37 Million EUR | 0.0% |
| 2022 FY | -60.72 Million EUR | 67.09% |
| 2022 Q4 | -60.72 Million EUR | 0.0% |
| 2021 Q4 | -184.52 Million EUR | 0.0% |
| 2021 FY | -184.52 Million EUR | -1358.5% |
| 2021 Q2 | -33.44 Million EUR | 0.0% |
| 2020 Q4 | 14.66 Million EUR | 0.0% |
| 2020 Q2 | -41.08 Million EUR | 0.0% |
| 2020 FY | 14.66 Million EUR | 115.74% |
| 2019 Q4 | -93.12 Million EUR | 0.0% |
| 2019 Q2 | -99.88 Million EUR | 0.0% |
| 2019 FY | -93.12 Million EUR | -147.32% |
| 2018 Q4 | -37.65 Million EUR | 0.0% |
| 2018 Q2 | -74.05 Million EUR | 0.0% |
| 2018 FY | -37.65 Million EUR | 65.79% |
| 2017 Q4 | -110.06 Million EUR | 0.0% |
| 2017 FY | -110.06 Million EUR | 24.62% |
| 2017 Q2 | -117.78 Million EUR | 0.0% |
| 2016 Q4 | -146.02 Million EUR | 0.0% |
| 2016 FY | -146.02 Million EUR | -168.4% |
| 2016 Q2 | -88.65 Million EUR | 0.0% |
| 2015 Q4 | -54.4 Million EUR | 0.0% |
| 2015 FY | -54.4 Million EUR | 21.61% |
| 2015 Q2 | -59.06 Million EUR | 0.0% |
| 2014 Q4 | -69.4 Million EUR | 0.0% |
| 2014 Q2 | -58.94 Million EUR | 0.0% |
| 2014 FY | -69.4 Million EUR | -411.37% |
| 2013 Q4 | -13.57 Million EUR | 0.0% |
| 2013 Q2 | -20.55 Million EUR | 0.0% |
| 2013 FY | -13.57 Million EUR | -408.58% |
| 2012 Q4 | 4.39 Million EUR | 0.0% |
| 2012 Q2 | -11.05 Million EUR | 0.0% |
| 2012 FY | 4.39 Million EUR | 240.69% |
| 2011 Q2 | -10.18 Million EUR | 0.0% |
| 2011 Q4 | 1.29 Million EUR | 0.0% |
| 2011 FY | 1.29 Million EUR | 109.26% |
| 2010 FY | -13.94 Million EUR | -81.89% |
| 2010 Q4 | -13.94 Million EUR | 0.0% |
| 2010 Q2 | -18.01 Million EUR | 0.0% |
| 2009 FY | -7.66 Million EUR | -14.06% |
| 2009 Q4 | -7.66 Million EUR | 0.0% |
| 2009 Q2 | -18.76 Million EUR | 0.0% |
| 2008 FY | -6.72 Million EUR | 44.6% |
| 2007 FY | -12.12 Million EUR | 32.45% |
| 2006 FY | -17.95 Million EUR | -161.61% |
| 2005 FY | -6.86 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | -965.966% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 96.126% |
| Adocia SA | 127 Thousand EUR | 6092.913% |
| Aelis Farma SA | -16.19 Million EUR | 52.995% |
| Biophytis S.A. | 2.7 Million EUR | 381.576% |
| Advicenne S.A. | 12.17 Million EUR | 162.513% |
| genOway Société anonyme | 2.97 Million EUR | 356.007% |
| IntegraGen SA | -709.74 Thousand EUR | -972.351% |
| Medesis Pharma S.A. | 1.15 Million EUR | 757.135% |
| Neovacs S.A. | -237.08 Thousand EUR | -3110.214% |
| NFL Biosciences SA | -2.27 Million EUR | -234.422% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 274.704% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | -816.383% |
| Sensorion SA | 1.37 Million EUR | 652.233% |
| Theranexus Société Anonyme | 2.44 Million EUR | 411.396% |
| TME Pharma N.V. | -1.07 Million EUR | -605.375% |
| Valbiotis SA | -18.13 Million EUR | 58.041% |
| TheraVet SA | 12.78 Thousand EUR | 59630.7% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 449.128% |
| argenx SE | -1.83 Billion EUR | 99.586% |
| BioSenic S.A. | 28.04 Million EUR | 127.139% |
| Celyad Oncology SA | -6.1 Million EUR | -24.73% |
| DBV Technologies S.A. | -114.95 Million USD | 93.379% |
| Galapagos NV | -157.2 Million EUR | 95.159% |
| GeNeuro SA | 5.91 Million EUR | 228.773% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 69.692% |
| Innate Pharma S.A. | -30.71 Million EUR | 75.218% |
| Inventiva S.A. | 10.48 Million EUR | 172.562% |
| MaaT Pharma SA | -10.2 Million EUR | 25.419% |
| MedinCell S.A. | 39.5 Million EUR | 119.268% |
| Nanobiotix S.A. | -24.71 Million EUR | 69.209% |
| Onward Medical N.V. | -12.89 Million EUR | 40.973% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 632.113% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 128.055% |
| Oxurion NV | 10.71 Million EUR | 171.064% |
| Pharming Group N.V. | 99.4 Million EUR | 107.657% |
| Poxel S.A. | 44.55 Million EUR | 117.081% |
| GenSight Biologics S.A. | 16.29 Million EUR | 146.71% |
| Transgene SA | -14.4 Million EUR | 47.179% |
| Financière de Tubize SA | 78.62 Million EUR | 109.68% |
| UCB SA | 2.17 Billion EUR | 100.35% |
| Valneva SE | 82.73 Million EUR | 109.199% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 58.913% |